About n.c.a. Lutetium-177 / EndolucinBeta®
EndolucinBeta®, no carrier-added (n.c.a.) Lutetium-177 (177Lu) chloride, is a radiopharmaceutical precursor used in Targeted Radionuclide Therapy for the treatment of various diseases, like cancer. When labeled with a disease-specific carrier molecule (e.g. peptide or antibody), the targeted radiopharmaceutical binds to a tumor specific receptor, according to the lock and key principle. EndolucinBeta® has a half-life of 6.647 days. No-carrier-added Lutetium-177 provides the highest specific activity of more than 3,000 GBq/mg at Activity Reference Time (ART), whereas the day of calibration can be flexibly selected by the customer. Optimal preconditions for efficient radiolabeling of biomolecules over its entire shelf-life of 9 days after production are ensured. EndolucinBeta® exhibits an extraordinary level of radionuclidic purity. EndolucinBeta® does not contain metastable Lutetium-177m. Thus, there is no need for cost intensive clinical disposal management and EndolucinBeta® can therefore be used globally – also in regions facing strict radiation protection regulations.



About ITM Isotopen Technologien München
ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors such as lung, ovarian or breast cancer. ITM's main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

Back to HCB News

Molecular Imaging Homepage